CTLA4 and non-small cell lung carcinoma: This explanation may also apply to sq-NSCLC (15) Nivolumab, a fully human anti-PD-1 antibody, and ipilimumab, a fully human anti-CTLA4 antibody, are ICIs with distinct but complementary mechanisms of action.